Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of DR10624 injection in metabolic dysfunction-associated fatty liver disease with high risk of liver fibrosis
CTR20250525Phase 2Active
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DR10624 in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Zhejiang Daer Biotechnology. Started Apr 2025; status: active.
02
Drugs
DR10624
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20250525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250525.